LexaGene Holdings Inc said its MiQLab System will be featured at some of the veterinary industry’s landmark events in Las Vegas, Nashville, and San Antonio beginning on September 7 through until September 26, 2021.
The company noted that the on-site demonstrations will spotlight how MiQLab’s next-generation technology is advancing veterinary polymerase chain reaction (PCR) diagnostic testing.
“We expect MiQLab’s in-person presence will have significant impact in the veterinary marketplace and look forward to demonstrating how vet practices will greatly benefit from in-clinic PCR diagnostics,” LexaGene CEO Dr Jack Regan said in a statement.
READ: LexaGene demonstrates simple, inexpensive multiplex PCR chemistry with shorter lead times for its MiQLab System
“Our attendance allows us to take a full-on approach with building brand awareness, exciting potential buyers, and improving our market reach through our revamped marketing and sales strategies,” Dr Regan added.
At this year’s WVC 93rd Annual Conference in Las Vegas, Dr Regan will speak on the topic of “In-Clinic PCR Testing for Pathogen ID and Antibiotic Resistance Detection.”
As well, Dr Regan will continue to participate in the strategic investor relations conferences listed here.
LexaGene Holdings is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety as well as for use in open-access markets such as clinical research, agricultural testing, and biodefense.
The company’s MiQLab system delivers excellent sensitivity, specificity, and breadth of detection, and can test for 27 pathogens and return results in about one hour versus 1-3 days at a lab.
Contact Sean at sean@proactiveinvestors.com